Cardiva Medical

Cardiva Medical was a private medical device company with headquarters in Santa Clara, California, specializing in vascular closure. The Company manufactured and sold vascular closure products that enabled rapid hemostasis following diagnostic and interventional endovascular procedures.

​Cardiva Medical offered products that covered a range of catheter-based coronary, peripheral, and electrophysiology (“EP”) procedures. The Company’s products were designed to address the challenges and limitations of existing closure techniques, and were shown to improve patient outcomes through lower complication rates while simultaneously improved hospital workflow. Cardiva’s VASCADE portfolio consisted of two devices: VASCADE and VASCADE MVP (“MVP”), both of which utilized a catheter-based delivery system to stimulate the natural blood clotting abilities of collagen. VASCADE was marketed for coronary and peripheral procedures and was clinically proven to reduce access site complications compared to manual compression. Cardiva Medical was sold to Haemonetics Corporation in March 2021 in an all-cash transaction valued at $510 million, consisting of $475 million up front and up to $35 million in performance-based milestones.